Virax Biolabs Group Ltd
VRAX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for VRAX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · VRAX
Virax Biolabs Group Ltd is a Cayman Islands biotechnology holding company focused on T cell-based immune profiling and in vitro diagnostics for post-acute infection syndromes, with its lead platform ViraxImmune™ still in development and not yet approved for diagnostic use.
Key risk: No approved products
Market Cap
$2.2M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Mar 31, 2025.
Virax Biolabs Group Ltd is a Cayman Islands biotechnology holding company focused on T cell-based immune profiling and in vitro diagnostics for post-acute infection syndromes, with its lead platform ViraxImmune™ still in development and not yet approved for diagnostic use.
- Virax Biolabs is a biotechnology company focused on immune response detection, T cell immune profiling and in vitro diagnostics for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) [sec · filed 2026-07-06].
- The company's lead platform, ViraxImmune™, is intended to measure and characterize T cell immune responses and is in development; it has completed a pre-submission meeting with the FDA to inform regulatory planning [sec · filed 2026-07-06].
- As of March 31, 2026, the company had cash and equivalents of $6.4 million, an accumulated deficit of $29.6 million, and current liabilities of $0.7 million [sec · filed 2026-07-06].
- The company has not generated any significant revenue from operations and expects to continue incurring losses for the foreseeable future [sec · filed 2026-07-06].
- Virax Biolabs was incorporated in the Cayman Islands and conducts operations through subsidiaries in the UK, US, and China; it commenced operations in 2013 [sec · filed 2026-07-06].
What works
- The company has completed a pre-submission meeting with the FDA, which may help clarify the regulatory pathway for ViraxImmune™ [sec · filed 2026-07-06].
- ViraxImmune™ is being developed for a large and growing area—post-acute infection syndromes—which could address an unmet medical need [sec · filed 2026-07-06].
- The company is advancing clinical validation activities with Emory University and UK-based partners to generate evidence for its PAIS-focused program [sec · filed 2026-07-06].
- The company has a cash balance of $6.4 million as of March 31, 2026, which may support near-term development activities [sec · filed 2026-07-06].
What to weigh
- ViraxImmune™ is still in development and not approved for diagnostic use in any jurisdiction; there is no assurance it will receive regulatory approval or achieve commercial adoption [sec · filed 2026-07-06].
- The company has an accumulated deficit of $29.6 million as of March 31, 2026, and has not generated any significant revenue from operations [sec · filed 2026-07-06].
- The company expects to continue incurring losses and may require additional capital to fund research, development, and commercialization efforts [sec · filed 2026-07-06].
- As a holding company with no material operations of its own, Virax Biolabs depends on its subsidiaries and faces risks common to early-stage biotechnology companies [sec · filed 2026-07-06].
From the filings
Quoted directly from source documents.
ViraxImmune is in development and not approved for diagnostic use.
“ViraxImmune™ remains in development and is not approved for diagnostic use in any jurisdiction.”
SEC filings · July 6, 2026
The company has an accumulated deficit of $29.6 million as of March 31, 2026.
“As of March 31, 2026, we had an accumulated deficit of $29,612,994.”
SEC filings · July 6, 2026
The company's current strategic focus is on post-acute infection syndromes.
“The Company's current strategic focus is on post-acute infection syndromes ("PAIS") and related areas of chronic immune dysfunction.”
SEC filings · July 6, 2026
The company has not generated significant revenue from operations.
“At present, we have not generated any significant revenue from existing operations.”
SEC filings · July 6, 2026
Risks & what to watch (4)›
Key risks
- No approved products — ViraxImmune is not approved for diagnostic use in any jurisdiction; regulatory approval is uncertain [sec · filed 2026-07-06].
- History of losses — Accumulated deficit of $29.6M as of March 31, 2026; no significant revenue generated [sec · filed 2026-07-06].
- Need for additional capital — Company may require further financing to fund R&D and commercialization; cash runway limited [sec · filed 2026-07-06].
- Early-stage company risks — Holding company with no material operations; faces typical biotech development and commercialization risks [sec · filed 2026-07-06].
What to watch
- Regulatory progress for ViraxImmune™ following the FDA pre-submission meeting [sec · filed 2026-07-06].
- Clinical validation results from studies with Emory University and UK partners [sec · filed 2026-07-06].
- Cash burn rate and any future capital raises, given the $6.4M cash balance as of March 31, 2026 [sec · filed 2026-07-06].
- Any announcements regarding commercial partnerships or laboratory adoption of the LDT pathway [sec · filed 2026-07-06].
Sources: SEC filings · Generated August 27, 2026 · How we verify sources →
Run Virax Biolabs Group Ltd through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Virax Biolabs Group Ltd facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
2
Total value held
$193K
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 878,803 | $193K |
| osaic holdings, inc. | 20 | $4 |
Short Interest
as of May 22, 2026- % of float
- 2.0%
- Days to cover
- 0.0
- Shares short
- 143,206
- Daily short volume (May 1, 2026)
- 35.1%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
VRAX short interestFrequently asked questions
What is the AI investment thesis for Virax Biolabs Group Ltd?
Virax Biolabs Group Ltd is a Cayman Islands biotechnology holding company focused on T cell-based immune profiling and in vitro diagnostics for post-acute infection syndromes, with its lead platform ViraxImmune™ still in development and not yet approved for diagnostic use.
Who is the CEO of Virax Biolabs Group Ltd?
Mr. James Foster is the chief executive officer of Virax Biolabs Group Ltd (VRAX).
Where is Virax Biolabs Group Ltd headquartered?
Virax Biolabs Group Ltd (VRAX) is headquartered in Lanarkshire, United Kingdom.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.